PRF Technologies shares are trading higher after the company announced expanded results from its preclinical study directly comparing its lead product candidate, PRF-110, to approved ZYNRELEF.
PRF Technologies shares are trading higher after the company announced expanded results from its preclinical study directly comparing its lead product candidate, PRF-110, to approved ZYNRELEF.
benzinga_article
PRF Technologies shares are trading higher after the company announced expanded results from its preclinical study directly comparing its lead product candidate, PRF-110, to approved ZYNRELEF.
